ThromboGenics NV News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.09.23	Oxurion Publishes First Half 2023 Results (GlobeNewswire)
27.09.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
18.09.23	Oxurion Receives First EUR 1 Million under Amended Atlas Funding Program (GlobeNewswire)
18.09.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
18.09.23	Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC (GlobeNewswire)
11.09.23	Oxurion Announces Key Amendments to Atlas and Kreos/Pontifax Agreements Enabling KALAHARI Trial to Progress to Topline Results in 2023 (GlobeNewswire)
07.09.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
01.09.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
01.09.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
25.08.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
23.08.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
23.08.23	Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC (GlobeNewswire)
21.08.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
21.08.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
16.08.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
11.08.23	Oxurion Receives Funding of EUR One Million under Atlas Special Opportunities LLC (Atlas) Funding Program (GlobeNewswire)
11.08.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
11.08.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
07.08.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
07.08.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
04.08.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
04.08.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
26.07.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
26.07.23	Oxurion Receives Transparency Notifications from Atlas Special Opportunities LL (GlobeNewswire)
25.07.23	Oxurion Receives Upfront Payment of $400,000 Following Oncurious Asset License by VIB (GlobeNewswire)
14.07.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
06.07.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
06.07.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
05.07.23	Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC (GlobeNewswire)
03.07.23	Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC (GlobeNewswire)
28.06.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
23.06.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
22.06.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
16.06.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
15.06.23	Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLC (GlobeNewswire)
15.06.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas (GlobeNewswire)
12.06.23	Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC (GlobeNewswire)
12.06.23	Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema (GlobeNewswire)
09.06.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS (GlobeNewswire)
06.06.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS (GlobeNewswire)
05.06.23	Oxurion Announces Results of the Extraordinary Shareholders’ Meeting of 22 May 2023 (GlobeNewswire)
01.06.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
01.06.23	Oxurion to Participate in Upcoming Conferences (GlobeNewswire)
31.05.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS (GlobeNewswire)
26.05.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS (GlobeNewswire)
25.05.23	Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema (GlobeNewswire)
22.05.23	Oxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLC (GlobeNewswire)
19.05.23	Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC (GlobeNewswire)
15.05.23	Oxurion Announces Results of the Annual Shareholders’ Meeting of 2 May 2023 (GlobeNewswire)
12.05.23	Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu ThromboGenics NV

Aktien Top/Flop

Meistgelesene Nachrichten